45
Participants
Start Date
September 22, 2014
Primary Completion Date
December 10, 2015
Study Completion Date
December 10, 2015
Selinexor (KPT-330)
Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly in 28-days cycle.
Herbert Irving Comprehensive Cancer Center / Columbia University, New York
Lee Moffitt Cancer Center and Research Institute, Tampa
Sarah Cannon Research Institute - Tennessee Oncology, Nashville
Vanderbilt-Ingram Cancer Center / Vanderbilt University, Nashville
Gabrail Cancer Center, Canton
Karmanos Cancer Institute, Detroit
Northwestern University, Evanston
University of Washington, Seattle
Washington University School of Medicine / Washington University in St. Louis, St Louis
Mary Crowley Cancer Research Center / Texas Oncology, Dallas
University of Colorado Cancer Center, Aurora
Oregon Health and Science University, Portland
Tufts Medical Center, Boston
Dana-Farber Cancer Institute / Harvard University, Boston
Metrowest Medical Center, Framingham
Hackensack University Medical Center, Hackensack
Icahn School of Medicine at Mount Sinai, New York
Princess Margaret Hospital, Toronto
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY